Post-earnings recap
Reported
Tue, Nov 14, 2017
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The lack of revenue data and guidance contributed to a significant drop in Soleno Therapeutics' stock price, which fell by 12.08%. Investors may be concerned about the company's future performance and the absence of specific financial targets. This uncertainty could lead to increased volatility in the stock moving forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.24 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management expressed caution regarding the current market conditions. They emphasized their commitment to advancing their product pipeline.
Management did not provide specific revenue figures or guidance for future quarters.
The focus remains on ongoing product development and regulatory processes.